HomeTrialNCT07100119
🔬NCT07100119Phase 1RECRUITING

A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis

Study Summary

The purpose of this study is to evaluate how well LY4256984 is tolerated and what side effects may occur in participants with sporadic amyotrophic lateral sclerosis (ALS). The study drug will be administered intrathecally (IT) into the spine. Blood tests will be performed to check how much LY4256984 gets into the bloodstream and how long it takes the body to eliminate it.

Interventions / Drugs
View on ClinicalTrials.gov ↗
Study Details
Enrollment32 participants
Primary Completion
Lead SponsorEli Lilly and Company
Data Retrieved2026-04-11 02:55:33.865881+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.